Skip to main content
Fig. 2 | BMC Health Services Research

Fig. 2

From: Health outcomes of bedaquiline in the treatment of multidrug-resistant tuberculosis in selected high burden countries

Fig. 2

Probability that bedaquiline plus BR will be cost-effective compared with BR alone. conducted to assess whether the addition of bedaquiline to BR, for a range of different prices that satisfy the WHO CE threshold (3x GDP), would be cost-effective. BR: background regimen; CE: cost-effectiveness; GDP: gross domestic product; WHO: World Health Organization

Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us